A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Sponsor:

BeOne Medicines Ltd

Sponsor Study ID:

BGB-16673-304

CTO #:

104291

NCT Number:

NCT06973187

Phase:

III

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Non-Hodgkin's Lymphoma

Study Objectives:

Progression-Free Survival (PFS) per Independent Review Committee (IRC) [Time Frame: Up to approximately 3 years] PFS is defined as time from the date of randomization to the date of first disease progression or death, whichever occurs first, as determined by IRC using modified 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria for participants with chronic lymphocytic leukemia (CLL) and Lugano classification for participants with small lymphocytic lymphoma (SLL).

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)